A cross-sectional quantitative analysis of the natural history of free sialic acid storage disease-an ultra-orphan multisystemic lysosomal storage disorder

被引:13
|
作者
Zielonka, Matthias [1 ,2 ,3 ]
Garbade, Sven F. [1 ,3 ]
Koelker, Stefan [1 ,3 ]
Hoffmann, Georg F. [1 ,3 ]
Ries, Markus [1 ,3 ]
机构
[1] Univ Heidelberg Hosp, Ctr Pediat & Adolescent Med, Div Pediat Neurol & Metab Med, Heidelberg, Germany
[2] HRCMM, Heidelberg, Germany
[3] Univ Heidelberg Hosp, Ctr Rare Dis, Heidelberg, Germany
关键词
Sialic acid storage disease; SLC17A5; Natural history; Drug development; Orphan disease; TRANSPORTER;
D O I
10.1038/s41436-018-0051-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Quantitative definition of the natural history of free sialic acid storage disease (SASD, OMIM 604369), an orphan disorder due to the deficiency of the proton-driven carrier SLC17A5. Methods: Analysis of published cases with SASD (N = 116) respecting STROBE criteria. Main outcome parameters: survival and diagnostic delay. Phenotype, phenotype-biomarker associations, and geographical patient distribution were explored. Results: Median age at disease onset was 0.17 years. Median age at diagnosis was 3 years with a median diagnostic delay of 2.5 years. Median survival was 11 years. The biochemical phenotype clearly predicted the disease course: patients with a urinary free sialic acid excretion below 6.37-fold or an intracellular free sialic acid storage in fibroblasts below 7.37-fold of the mean of normal survived longer than patients with biochemical values above these thresholds. Cluster analysis of disease features suggested a continuous phenotypic spectrum. Patient distribution was panethnic. Conclusion: Combination of neurologic symptoms, visceromegaly, and dysmorphic features and/or nonimmune hydrops fetalis should prompt specific tests for SASD, reducing diagnostic delay. The present quantitative data inform clinical studies and may stimulate and accelerate development of specific therapies. Biomarker-phenotype association is particularly important for both counseling parents and study design.
引用
收藏
页码:347 / 352
页数:6
相关论文
共 4 条
  • [1] Ultra-orphan lysosomal storage diseases: A cross-sectional quantitative analysis of the natural history of alpha-mannosidosis
    Zielonka, Matthias
    Garbade, Sven F.
    Koelker, Stefan
    Hoffmann, Georg F.
    Ries, Markus
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2019, 42 (05) : 975 - 983
  • [2] A cross-sectional quantitative analysis of the natural history of Farber disease: an ultra-orphan condition with rheumatologic and neurological cardinal disease features
    Zielonka, Matthias
    Garbade, Sven F.
    Kolker, Stefan
    Hoffmann, Georg F.
    Ries, Markus
    [J]. GENETICS IN MEDICINE, 2018, 20 (05) : 524 - 530
  • [3] FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis
    Garbade, Sven F.
    Zielonka, Matthias
    Mechler, Konstantin
    Koelker, Stefan
    Hoffmann, Georg F.
    Staufner, Christian
    Mengel, Eugen
    Ries, Markus
    [J]. PLOS ONE, 2020, 15 (04):
  • [4] Quantitative longitudinal natural history of 8 gangliosidoses-conceptual framework and baseline data of the German 8-in-1 disease registry. A cross-sectional analysis
    Ries, Markus
    Mendoza, Grecia
    Arash-Kaps, Laila
    Amraoui, Yasmina
    Quack, Folker
    Hardt, Brigitte
    Diederich, Stefan
    Beck, Michael
    Mengel, Eugen
    [J]. GENETICS IN MEDICINE, 2022, 24 (12) : 2434 - 2443